- Home
- FMS vs EXEL Comparison
FMS vs EXEL Comparison
Compare FMS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMS | EXEL |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 12.7B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FMS | EXEL |
|---|---|---|
| Price | $22.60 | $71.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $23.77 | ★ $59.79 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.46 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | N/A | $10.16 |
| Revenue Next Year | $3.49 | $12.43 |
| P/E Ratio | ★ $15.62 | $28.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.02 | $37.58 |
| 52 Week High | $26.42 | $72.10 |
Technical Indicators
Market Signals| Indicator | FMS | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 84.26 |
| Support Level | $22.05 | $54.85 |
| Resistance Level | $23.03 | N/A |
| Average True Range (ATR) | 0.42 | 1.80 |
| MACD | 0.13 | 0.64 |
| Stochastic Oscillator | 76.13 | 93.14 |
Price Performance
Historical ComparisonAbout FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.